9 Results for "

Ramos B cells

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "Ramos B cells" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-15322
CAS No.: 1370261-96-3
Purity:  99.38%
Synonyms: P505-15; PRT-2607; BIIB-057
Target:  

Syk Apoptosis Caspase

Research Areas:  

Inflammation/Immunology Cancer

PRT062607 (P505-15; PRT-2607) is an orally active ATP-competitive Syk inhibitor with an IC50 value of 1 nM, and exhibits at least 80-fold selectivity over other kinases. PRT062607 blocks B cell antigen receptor-mediated activation, Fcε receptor 1-mediated basophil degranulation and microglial phagocytosis, and induces caspase-dependent apoptosis and microglial death. PRT062607 inhibits tumor growth and peripheral nerve injury-induced mechanical allodynia, and prevents neuronal loss. PRT062607 can be used in research related to rheumatoid arthritis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, neurodegenerative diseases and neuropathic pain .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99272
CAS No.: 1375830-34-4
Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody

Target:  

CXCR

Research Areas:  

Cancer

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
loading...
    loading...
Cat. No.: HY-15809
CAS No.: 936563-91-6
Target:  

Btk Calcium Channel

Research Areas:  

Inflammation/Immunology

(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. (Rac)-Ibrutinib alkyne can effectively inhibit functions related to the B-cell receptor signaling pathway, with an IC50 of 9 nM for inhibiting Ca flux in Ramos cells. (Rac)-Ibrutinib alkyne can be used in the research of diseases such as rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-122830
CAS No.: 2366132-45-6
Purity:  98.72%
Target:  

PROTACs Btk NF-κB

Research Areas:  

Cardiovascular Disease Cancer

DD-03-171 is a PROTAC BTK degrader. DD-03-171 inhibits mantle cell lymphoma (MCL) cell proliferation (IC50 = 5.1 nM) and prolongs the survival of mice bearing a lymphoma PDX model by degrading BTK, IKFZ1, and IKFZ3. DD-03-171 also inhibits platelet function and thrombosis. (Pink: BTK ligand 9 (HY-168292); Black: linker (HY-28875); Blue: Thalidomide-NH-CH2-COOH (HY-131717)) .
loading...
    loading...
Cat. No.: HY-176071
Research Areas:  

Cancer

TEC 4 is a ByeTAC (Bypassing E-Ligase-Targeting Chimera) BRD4 degrader, with 33% BRD4 remaining at 500 nM in Ramos B-cells. TEC 4 shows toxicity for Ramos B-cells, with an IC50 of 30.5 nM. ByeTACs directly recruits a protein to the proteasome via interactions with Rpn-13 for degradation. Pink: BRD4 lignad (HY-78695); Blue: Rpn-13 ligand (HY-159808); Black: linker (HY-W008352) .
loading...
    loading...
Cat. No.: HY-145884
CAS No.: 2824922-28-1
Target:  

Btk

Research Areas:  

Inflammation/Immunology

BTK-IN-8 is a potent and selective peripheral covalent BTK inhibitor (IC50=0.22 nM; Kd=0.91 nM). BTK-IN-8 has good whole blood CD69 cellular potency (IC50=0.029 µM) .
loading...
    loading...
Cat. No.: HY-P992408

Research Areas:  

Cancer

MEDI-5083 is an Fc fusion protein that targets CD40 and is a CD40 agonist. MEDI-5083 stimulates CD40 signaling via NF-κB activation. MEDI-5083 upregulates MHCII, CD80, and CD86 expression, induces pro-inflammatory cytokine secretion, and enhances IFN-γ secretion by memory CD8+ T cells. MEDI-5083 can be used for the research of melanoma, colon carcinoma, and advanced solid tumors[1][2].
loading...
    loading...
Cat. No.: HY-125585
CAS No.: 1345458-66-3
Target:  

Syk

Research Areas:  

Others

Syk-IN-2 (Page 78; 35) is a spleen tyrosine kinase (Syk) inhibitor .
loading...
    loading...
Cat. No.: HY-187161
CAS No.: 3104023-25-5
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

IL-4-IN-3 (Compound 15/analog 15) is a selective, reversible small-molecule IL-4 inhibitor with a Kd of 31.9 nM for IL-4. IL-4-IN-3 inhibits IL-4-induced STAT6 phosphorylation in THP-1 monocytes and Ramos B lymphocytes. IL-4-IN-3 can be used in research related to allergic inflammation, cancer, autoimmune diseases, asthma and arthritis .
loading...
    loading...